Organisation paid for research Program year 2025 Source: CMS Open Payments

Wirbcopernicus Group Inc

Neither a doctor nor a teaching hospital

Research payments

$2,021,002

172 payments

Through program year 2025, Wirbcopernicus Group Inc is reported as receiving $2,021,002 in research payments, across 172 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$924,188	101
2024	Research	$1,096,537	70
2023	Research	$277	1

Breakdown

Who paid Research payments · program years 2023–2025

Sanofi Pasteur Inc. $1,424,014 121 payments
Sanofi US Services Inc. $594,718 50 payments
Genzyme Corporation $2,270 1 payment

Studies the money was for Research payments · program years 2023–2025

Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $1,504,354 145 payments
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $499,826 20 payments
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $5,710 2 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $5,710 2 payments
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $2,855 1 payment
Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma $2,270 1 payment
A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A $277 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.